不稳定型冠状动脉疾病的管理策略——当前问题与未来方向。UCAD委员会。
Management strategies in unstable coronary artery disease--current problems and future directions. The UCAD Council.
作者信息
Verheugt F W, Becker R C, Bertrand M E, Bode C, Chesebro J H, Cleland J G, Conti R, Hillis W S, Klein W, Maseri A, Turpie A G, Wallentin L, Waters D D
机构信息
Department of Cardiology, Academic Hospital Nijmegen St Radboud, The Netherlands.
出版信息
Clin Cardiol. 1999 Sep;22(9):551-3. doi: 10.1002/clc.4960220903.
Abstract
Unstable coronary artery disease continues to pose a major challenge to clinicians. The advent of new therapies, such as percutaneous transluminal coronary angioplasty, low-molecular-weight heparins, and glycoprotein IIb/IIIa inhibitors, provides new management options for this indication but also raises new questions with regard to optimal management. Prospective randomized trials with well-defined, long-term outcome measures and a means of identifying which patients will derive most benefit from each treatment, together with a means of rapid and clear dissemination of study results and implications, are required in order to advance the management of unstable coronary artery disease.
摘要
不稳定型冠状动脉疾病仍然是临床医生面临的重大挑战。经皮腔内冠状动脉成形术、低分子量肝素和糖蛋白IIb/IIIa抑制剂等新疗法的出现，为这一适应症提供了新的治疗选择，但也引发了关于最佳治疗方案的新问题。为了推进不稳定型冠状动脉疾病的治疗，需要进行前瞻性随机试验，采用明确的长期预后指标以及确定哪些患者将从每种治疗中获益最多的方法，同时还需要一种快速、清晰地传播研究结果及其意义的方法。
相似文献
1
Management strategies in unstable coronary artery disease--current problems and future directions. The UCAD Council.
Clin Cardiol. 1999 Sep;22(9):551-3. doi: 10.1002/clc.4960220903.
2
Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
Pharmacoeconomics. 2003;21(16):1135-52. doi: 10.2165/00019053-200321160-00001.
3
Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention.
JAMA. 2003 Jan 15;289(3):331-42. doi: 10.1001/jama.289.3.331.
4
Therapeutic adjuncts for immediate transfer to the catheterization laboratory in patients with acute coronary syndromes.
Am J Cardiol. 2000 Dec 28;86(12B):10M-17M. doi: 10.1016/s0002-9149(00)01476-4.
5
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
JAMA. 2000 Sep 27;284(12):1549-58. doi: 10.1001/jama.284.12.1549.
6
Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Vasc Health Risk Manag. 2006;2(1):39-48. doi: 10.2147/vhrm.2006.2.1.39.
7
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Am Heart J. 2003 Oct;146(4):628-34. doi: 10.1016/S0002-8703(03)00165-0.
8
Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes.
J Invasive Cardiol. 2003 Aug;15(8):460-5.
9
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Am Heart J. 2006 Jul;152(1):149-54. doi: 10.1016/j.ahj.2005.09.007.
10
Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical treatment of unstable coronary artery disease.
Haemostasis. 2000;30 Suppl 2:122-7; discussion 106-7. doi: 10.1159/000054177.
引用本文的文献
1
Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
Br J Clin Pharmacol. 2001 Sep;52(3):297-305. doi: 10.1046/j.0306-5251.2001.01446.x.
本文引用的文献
1
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.
Circulation. 1998;98(25):2829-35. doi: 10.1161/01.cir.98.25.2829.
2
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.
Circulation. 1998 Sep 15;98(11):1064-70. doi: 10.1161/01.cir.98.11.1064.
3
TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators.
Am Heart J. 1998 Jun;135(6 Pt 3 Su):S353-60. doi: 10.1016/s0002-8703(98)70265-0.
4
Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis.
Circulation. 1998;97(1):26-33. doi: 10.1161/01.cir.97.1.26.
5
Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).
Am J Cardiol. 1997 Sep 4;80(5A):61E-63E. doi: 10.1016/s0002-9149(97)00493-1.
6
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
N Engl J Med. 1997 Aug 14;337(7):447-52. doi: 10.1056/NEJM199708143370702.
7
Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study.
J Am Coll Cardiol. 1997 Aug;30(2):364-9. doi: 10.1016/s0735-1097(97)00153-8.
8
Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
Circulation. 1997 Jul 1;96(1):61-8. doi: 10.1161/01.cir.96.1.61.
9
Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.
J Am Coll Cardiol. 1997 Jan;29(1):43-8. doi: 10.1016/s0735-1097(96)00447-0.
Zotero 插件